Tumor Development Analysis
Tumor Development Analysis - Related Videos
09:26
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
0 Views •
Cited by 8 •
2011
Here, we established a method for drug efficacy testing with surgical specimens of brain tumors, termed “tumor explant method”. With this method, we can evaluate drug efficacy without breaking the microenvironment of solid tumors. To validate reliability of this method, we describe representative data with our glioma specimen treated with the current first-line chemotherapeutic agent, temozolomide.
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
11:09
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
0 Views •
Cited by 104 •
2010
Luciferase-modified human brain tumor xenografts can be established intracranially in athymic mice, with subsequent monitoring of tumor growth and response to therapy using bioluminescence imaging. In combination with survival analysis, bioluminescence monitoring is an essential research tool for pre-clinical testing of therapies being considered for treating brain tumors.
08:01
Analysis of Developing Tooth Germ Innervation Using Microfluidic Co-culture Devices
0 Views •
Cited by 10 •
2015
Co-cultures represent a valuable method to study the interactions between nerves and target tissues and organs. Microfluidic systems allow co-culturing ganglia and whole developing organs or tissues in different culture media, thus representing a valuable tool for the in vitro study of the crosstalk between neurons and their targets.
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
0 Views •
Cited by 23 •
2016
Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.
FAQs
Genetic and epigenetic alterations provide evidence of how abnormal cells lose normal growth control. Their effects can be examined alongside changes in proliferation, cell-death avoidance, microenvironment remodeling, angiogenesis, and tissue invasion. Comparing these molecular changes across tumor stages helps researchers connect underlying alterations with observable progression and identify features that may support biomarker discovery or treatment studies.
These features represent interconnected aspects of tumor progression rather than isolated observations. Avoiding cell death can support continued expansion, microenvironment remodeling can alter the surroundings of tumor cells, angiogenesis can accompany tumor growth, and invasion indicates movement into nearby tissues. Assessing them together gives a broader picture of how tumors acquire increasingly aggressive characteristics.
Stage-by-stage analysis shows how tumor characteristics change as disease develops. Researchers can compare genetic and epigenetic alterations with histological appearance, imaging findings, and functional behavior at different points. This longitudinal perspective helps distinguish early changes from later features such as tissue invasion or altered treatment response, strengthening interpretation of disease progression.
Treatment response can be evaluated by combining molecular profiling, imaging, histological evaluation, and functional assays. These approaches examine whether tumor-associated molecular features, visible tissue characteristics, or measured cellular behaviors change after treatment. The resulting evidence can help researchers characterize response, investigate progression, and support drug development or strategies intended to limit recurrence.
A supported workflow begins by examining tumors across relevant stages, followed by molecular profiling, imaging, histological evaluation, and functional assays. Researchers then compare the resulting observations to identify changes in genetic or epigenetic features, tissue appearance, cellular behavior, and progression-related traits. Integrating these data supports interpretation of tumor development rather than relying on one measurement alone.
Molecular profiling characterizes genetic and epigenetic alterations, while imaging and histological evaluation document tumor features and tissue-level changes. Functional assays add information about cellular behavior, including properties relevant to progression or treatment response. Using these methods together connects molecular findings with visible and functional outcomes, creating a more complete analysis for cancer research.
Researchers use patterns identified during tumor development analysis to support biomarker discovery and patient stratification. Molecular, imaging, histological, and functional findings can help distinguish tumors according to their progression-related characteristics or treatment responses. These distinctions may guide the design of cancer studies, improve comparison among tumor groups, and inform development of approaches aimed at limiting progression or recurrence.